BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Eli Lilly Japan K.K. (LLY) Obtains Additional Approval For Its Anti-cancer Agent Gemzar Injection


7/10/2006 11:00:04 AM

Tokyo, July 10, 2006 (JCN) - Eli Lilly Japan announced o June 4 that it has obtained additional approval for Gemzar Injection (gemcitabine HC1), its proprietary anti-cancer agent, from the Ministry of Health, Labor and Welfare. The agent will now be available for the treatment of biliary tract cancer.

Initially approved in Japan in March 1999, Gemzar is currently indicated for the treatments of non-small cell lung cancer and pancreatic cancer.

The company expects that Gemzar, with its superior response rate and reduced side effects, will be an optimal choice for patients with biliary tract cancer.



Read at JCN Newswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES